Value in Health
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
HEALTH STATES UTILITIES FOR ALLERGIC RHINITIS - AN AI-SUPPORTED SYSTEMATIC REVIEW
2024
-
ASSESSMENT OF THE COST-EFFECTIVENESS OF RISK FACTOR GUIDED PROPHYLAXIS WITH PALIVIZUMAB FOR THE PREVENTION OF SEVERE RESPIRATORY SYNCYTIAL VIRUS INFECTION IN COLOMBIAN INFANTS BORN AT 32-35 WEEKS' GESTATIONAL AGE
2023
-
CURRENT TRENDS IN QUANTITATIVE BIAS ANALYSIS FOR UNMEASURED CONFOUNDERS: A TARGETED LITERATURE REVIEW
2023
-
OPTIMIZING THE USE OF RISK FACTORS TO GUIDE THE COST-EFFECTIVE USE OF PALIVIZUMAB PROPHYLAXIS AGAINST SEVERE RESPIRATORY SYNCYTIAL VIRUS INFECTION IN KOREAN INFANTS BORN 32-35 WEEKS' GESTATIONAL AGE
2023
-
The Associations of Prescription Drug Insurance and Cost-Sharing With Drug Use, Health Services Use, and Health: A Systematic Review of Canadian Studies
2023
-
AI SUPPORT REDUCED SCREENING BURDEN IN A SYSTEMATIC REVIEW WITH COSTS AND COST-EFFECTIVENESS OUTCOMES (SR-CCEO) FOR COST-EFFECTIVENESS MODELING
2023
-
ASSOCIATION BETWEEN THE SARCOMATOID STATUS AND PERCENTAGE OF SARCOMATOID ON THE CLINICAL OUTCOMES OF LOCALIZED RENAL CELL CARCINOMA POST NEPHRECTOMY
2022
-
CLINICAL OUTCOMES OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) WITH OR WITHOUT SARCOMATOID DIFFERENTIATION TREATED WITH SYSTEMIC THERAPY IN REAL-WORLD CANADIAN SETTING
2022
-
DEVELOPMENT AND APPLICATION OF A NEW COST-UTILITY MODEL TO ASSESS THE COST-EFFECTIVENESS OF PALIVIZUMAB FOR THE PREVENTION OF SEVERE RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION IN MODERATE-TO-LATE PRETERM INFANTS
2022
-
RESOURCE USE AND COSTS ASSOCIATED WITH COMPUTERIZED DECISION SUPPORT SYSTEM FOR MANAGING PATIENTS WITH ATRIAL FIBRILLATION
2022
-
TEN-YEAR EPIDEMIOLOGY, ECONOMIC BURDEN AND ALL-CAUSE MORTALITY AMONG GENERALIZED PUSTULAR PSORIASIS PATIENTS: A CANADIAN PREVALENCE STUDY OF INPATIENT CARE, EMERGENCY DEPARTMENTS, AND HOSPITAL- OR COMMUNITY-BASED OUTPATIENT CLINICS
2022
-
TEN-YEAR EPIDEMIOLOGY, ECONOMIC BURDEN AND ALL-CAUSE MORTALITY AMONG PALMOPLANTAR PUSTOLOSIS PATIENTS: A 10-YEAR CANADIAN PREVALENCE STUDY OF INPATIENT CARE, EMERGENCY DEPARTMENTS, AND HOSPITAL- OR COMMUNITY-BASED OUTPATIENT CLINICS
2022
-
Three-Year Epidemiology, Economic Burden and All-Cause Mortality Among Generalized Pustular Psoriasis Patients: A Canadian Incidence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics
2022
-
COST-EFFECTIVENESS OF EMICIZUMAB PROPHYLAXIS IN PATIENTS WITH HEMOPHILIA A WITHOUT INHIBITORS
2022
-
IMPACT OF DEPRESSION RELAPSE ON PARTICIPANT QUALITY OF LIFE AND COSTS TO THE ENGLISH NHS: SECONDARY ANALYSIS FROM THE ANTLER STUDY ON ANTIDEPRESSANT DISCONTINUATION IN WELL PATIENTS IN PRIMARY CARE
2022
-
THE IMPACT OF KEY HEALTH STATE TRANSITIONS ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN DUCHENNE MUSCULAR DYSTROPHY (DMD): A QUALITATIVE STUDY
2022
-
TIME TRADE-OFF UTILITY VALUES FOR HEALTH STATES CHARACTERIZING PROGRESSIVE MUSCULAR DEGENERATION IN DUCHENNE MUSCULAR DYSTROPHY (DMD)
2022
-
ECONOMIC COST OF IN CANADA: A MULTI-CENTRE, RETROSPECTIVE STUDY
2022
-
THE DRIVERS OF HEALTH STATE UTILITIES IN DUCHENNE MUSCULAR DYSTROPHY (DMD): A STUDY USING THE HEALTH UTILITIES INDEX MARK 3 (HUI3)
2021
-
WHAT IS VALUE? A SYSTEMATIC REVIEW OF VALUE ASSESSMENT FRAMEWORKS
2021
-
IMPROVING THE APPLICATION OF PUBLISHED HEALTH UTILITIES IN COST-UTILITY ANALYSES: DEVELOPMENT OF THE HEALTH UTILITY APPLICATION TOOL (HAT)
2020
-
COST-EFFECTIVENESS OF RIVAROXABAN IN THE TREATMENT OF PATIENTS WITH CHRONIC CAD OR PAD IN THE UK
2019
-
ECONOMIC EVALUATION METHODS IN ONCOLOGY: ONWARDS AND UPWARDS
2019
-
UTILITY VALUES FOR HEALTH STATES ASSOCIATED WITH DUCHENNE MUSCULAR DYSTROPHY: A SYSTEMATIC REVIEW
2019
-
PCN41 THE HEALTH UTILITY BOOK (HUB): A REGISTRY OF HEALTH STATE UTILITY VALUES IN ONCOLOGY
2019
-
PCN42 THE HEALTH UTILITY BOOK (HUB): TOWARD A CENTRALIZED, SYSTEMATIC APPROACH TO THE IDENTIFICATION, APPRAISAL, AND USE OF HEALTH STATE UTILITY VALUES FOR REIMBURSEMENT DECISION MAKING
2019
-
PNS88 IMPACT OF PATIENT-TARGETED FINANCIAL INCENTIVES ON HEALTHCARE COSTS: A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS
2019
-
ASSESSING THE IMPACT OF ACTIVE IDENTIFICATION OF PATIENTS APPROPRIATE FOR PALLIATIVE CARE ON RESOURCE UTILIZATION AND COSTS IN THE FINAL MONTH OF LIFE
2018
-
CE3 - COST-EFFECTIVENESS OF DEMENTIA CARE MANAGEMENT ALONGSIDE A CLUSTER-RANDOMIZED CONTROLLED INTERVENTIONAL DELPHI TRIAL
2018
-
PCN210 - USING REAL WORLD DATA TO DETERMINE HEALTH SYSTEM COSTS OF A 5-YEAR NON-SMALL CELL LUNG CANCER COHORT
2018
-
PCN221 - STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER TREATMENT PATTERNS AND COSTS: AN ONTARIO, CANADA ANALYSIS
2018
-
PMS32 - ASSESSING DIRECT AND INDIRECT HEALTH SYSTEM COSTS OF THE BUILD BETTER BONES WITH EXERCISE PILOT TRIAL
2018
-
PRM68 - IMPUTATION METHODS FOR MISSING DATA IN COST-UTILITY ANALYSES ALONGSIDE RANDOMIZED CONTROLLED TRIALS: AGGREGATE OR NON-AGGREGATE?
2018
-
Evaluation of Subcutaneous Rituximab Administration Impacts on Canadian Systemic Therapy Suites
2018
-
Evidence Driven Cancer Drug Approvals In Phase II Versus Phase III Clinical Trials Within A Single-Payer Public Healthcare System
2018
-
First Steps in Choosing Appropriate Instruments/Measurements for a Core Outcome Set: An Example from Corehem
2018
-
How Values Inform the Health Policy Decision-Making Processes About Health-System Financing in Latin America? A Critical Interpretive Synthesis
2018
-
Respiratory Illness (RI) and Respiratory Syncytial Virus (RSV)-Related Hospitalization (RSVH) in Infants with Congenital Diaphragmatic Hernia (CDH) in the Caress Registry (2005-2017)
2018
-
United States Valuation of EQ-5D-5L Health States: An Initial Model Using a Standardized Protocol
2018
-
Development of A New Patient-Reported Outcome Instrument To Evaluate Treatments For Stretchmarks: The Body-Q Stretchmark Scale
2017
-
Estimating the Comparative Accuracy of Diagnostic Tests: AN Example using Typhoid Fever
2017
-
Optimal Usage of Sacubitril/Valsartan For Heart Failure Treatment In Canada Potentially Reduces Mortality, Hospitalizations And Early Discharge Re-Admissions
2017
-
Reliability, Validity and Responsiveness of A New Measure of Neck Disability (ND10)
2017
-
Translation And Cultural Adaptation Of The Body-Q Chest Module Into Finnish For Use In Gynecomastia, Weight Loss And FTM Chest Surgery
2017
-
A META-EPIDEMIOLOGICAL SURVEY OF THE REPORTING OF EFFECT MODIFICATION IN NETWORK META-ANALYSES
2017
-
CONSIDERATIONS IN THE ECONOMIC EVALUATION OF NURSE PRACTITIONERS AND CLINICAL NURSE SPECIALISTS ROLES
2017
-
COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB IN PSORIATIC ARTHRITIS: A CANADIAN PERSPECTIVE
2017
-
RESPIRATORY ILLNESS AND RESPIRATORY SYNCYTIAL VIRUS (RSV)-RELATED HOSPITALIZATION (RSVH) IN INFANTS WITH CONGENITAL AIRWAY ANOMALIES (CAA) IN THE CARESS REGISTRY (2005-2016)
2017
-
ROBOTIC-ASSISTED THORACOSCOPIC PULMONARY RESECTION VERSUS VIDEO-ASSISTED THORACOSCOPIC PULMONARY RESECTION FOR EARLY STAGE NON-SMALL CELL LUNG CANCER: A HEALTHCARE UTILIZATION ANALYSIS
2017
-
Factors Influencing Door-To-Doctor Time In An Emergency Department: Discrete Event Simulation Model
2016
-
Linguistic Validation of the Finnish Version of the Body-Q Pro Instrument
2016
-
NETWORK META-ANALYSIS TO ASSESS THE RELATIVE EFFICACY AND SAFETY OF LINAGLIPTIN, EMPAGLIFLOZIN AND THE FIXED DOSE COMBINATION OF EMPAGLIFLOZIN AND LINAGLIPTIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
2016
-
Comparison Of First- And Second-Season Palivizumab Prophylaxis In Patients With Congenital Airway Anomalies (Caa) In The Caress Database (2005-2015)
2016
-
Dalteparin Versus Vitamin K Antagonists for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer and Renal Impairment: Pharmacoeconomic Analysis of a Prospective Randomized Trial
2016
-
Indirect Costs Associated with Cardiovascular Disease in Canada: A Literature Review
2016
-
NURSE-LED CARE FOR PATIENTS WITH RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW
2016
-
Trends In Oral Glucocorticoid Utilization Among Older Adults With Respiratory Disease
2016
-
Propensity Score Matching Does not Always Remove Confounding within an Economic Evaluation Based on a Non-Randomized Study
2015
-
The Cost-Effectiveness of Referring Patients With Irritable Bowel Syndrome To A Gastroenterologist In The Uk
2015
-
A review of health-related quality of life (hrql) claims in labels of asthma products – can we consider the asthma quality of life questionnaire (aqlq) as a potentially acceptable measure for qualification?
2015
-
Assure-Csu Canadian Results: Assessing Health Utility In Chronic Spontaneous/Idiopathic Urticaria Using The Eq-5d
2015
-
Comparing First- and Second-Season Palivizumab Prophylaxis In Patients with Hemodynamically Significant Congenital Heart Disease in the Caress Database (2005-2014)
2015
-
Respiratory Related Hospitalizations In Premature Infants Prophylaxed With Palivizumab In the Canadian Registry of Palivizumab (Caress)
2015
-
Serious Adverse Events In Canadian Children Receiving Palivizumab for the Prevention of Respiratory Syncytial Virus Infection
2015
-
The Economic Value of Tofacitinib 5 Mg Bid In The Treatment of Moderate To Severe Rheumatoid Arthritis: A Canadian Analysis
2015
-
The Processes For A Common Quality Assurance Approach To Multi-Centre Clinical Trials – The Mars Excite Experience
2015
-
Usability Testing Of The Web-Based Versions Of The Standardised Asthma Quality Of Life Questionnaire For 12 Years And Older (Aqlq(S)+12) And The Asthma Control Questionnaire (Acq-6)
2015
-
Acute And Chronic Impact Of Cardiovascular Events On Health State Utilities
2014
-
Concomitant Use of Non-Steroidal Anti-Inflammatory Drugs (Nsaids) And Proton Pump Inhibitors (Ppis) in Newly Diagnosed Patients With Osteoarthritis (Oa), Rheumatoid Arthritis (Ra) or Ankylosing Spondylitis (As)
2014
-
A systematic review of methodological frameworks for evaluation of ethical considerations in health technology assessment
2014
-
An Examination Of Disparity In Access To Mental Health Services Among People Living With Human Immunodeficiency Virus (Hiv) And Co-Morbid Depression In Ontario
2014
-
Burden of illness of diabetic foot ulcers in Canada
2014
-
Comparative efficacy and safety of golimumab, infliximab and adalimumab for the treatment of moderate to severe ulcerative colitis: A bayesian indirect treatment comparison meta-analysis
2014
-
Cost-Utility Analysis of Newer HER2- Testing Technologies to Target Trastuzumab in the Adjuvant Breast Cancer Setting
2014
-
Cost-Utility Analysis of Practice Deviations From Guidelines in HER2-Targeted Testing and Treatment for Breast Cancer
2014
-
Cost-effectiveness of golimumab versus infliximab and adalimumab for the treatment of moderate to severe ulcerative colitis
2014
-
Cost–Effectiveness Analysis Parallel to a Randomized Controlled Trial Comparing Vertical Scar Reduction (VSR) and Inverted T-Shaped Reduction (ITR) Mammoplasty
2014
-
EQ-5D health utilities are estimated subject to considerable uncertainty
2014
-
Evaluation Of A Chronic Disease Management System For The Treatment And Management Of Diabetes In Primary Health Care Practices In Ontario
2014
-
Factors associated with large increases in self-reported health status in infliximab-treated inflammatory bowel disease patients: results from the bioadvance survey
2014
-
First Two Years of Health System Resources and Costs Following a Stage Defined Breast Cancer Diagnosis: A Population Based Approach
2014
-
Follow-Up Of Psychoactive Drug Use In Newly Diagnosed Patients With Autism Spectrum Disorder (Asd) In Quebec (Canada)
2014
-
Health Care Resource Utilization in the Management of Chronic Lymphocytic Leukemia at an Ontario Cancer Centre
2014
-
Health State Utilities Associated With Attributes Of Treatments For Hepatitis C
2014
-
Increased In Acute Health Care Use Among People Living With Human Immunodeficiency Virus (Hiv) And Co-Morbid Depression In Ontario: A Longitudinal Study
2014
-
Mammographic Density in Association with Smoking Status and Smoking Histories in a Sample of Postmenopausal Women: Results From a Cross-Sectional Study
2014
-
Prevalence And Incidence Of Interstitial Pulmonary Diseases With Fibrosis
2014
-
Psychiatric Health Care Utilisation And Related Costs In Newly Diagnosed Patients With Autism Spectrum Disorder (Asd) In Quebec (Canada)
2014
-
Respiratory Syncytial Virus Prophylaxis In Down Syndrome: A Prospective Cohort Study
2014
-
Screening For Type 2 Diabetes: A Methodological Review And Cost Analysis
2014
-
Survival crossover adjustment and cost effectiveness analysis: An empirical and methodological review with application
2014
-
The Canadian Eq-5d Valuation Study: Estimating Time Trade-Off Values For The Eq-5d-5l
2014
-
The Cost-Effectiveness of 2nd Line Crizotinib in EML4-Alk Rearranged Advanced NSCLC in Ontario
2014
-
Time trade-off utility assessment with a 10-year time horizon: when should alternative approaches be considered?
2014
-
Use Of Economic Evidence To Inform Drug Reimbursement Decision Making: The Case For Ontario
2014
-
Adherence Interventions to Improve Adherence to Antiretroviral Therapy in Low Income Settings: An Individual Patient Data Network Meta-Analysis
2013
-
Assessment of a Canadian Primary Care Electronic Medical Record Database for Use in Observational Studies
2013
-
Cost-Effectiveness of EML4-ALK Fusion Testing and First-Line Crizotinib Treatment for Patients with Advanced ALK Positive Non-Small Cell Lung Cancer in a Publicly Funded System (Ontario, Canada)
2013
-
Development of an Interviewer-Administered Version of the Asthma Control Questionnaire (ACQ-IA) for 6-10 Year Old Patients in 11 Languages
2013
-
Easing Decision-Making by Expanding Methods of Multiple Treatment Comparison Meta-Analysis – Incorporating Non-Comparative Studies Via Informative Priors
2013
-
Factors Associated with Compliance with Palivizumab Prophylaxis in the Canadian RSV Evaluation Study for Synagis (CARESS) Registry (2005-2012)
2013
-
Health Utilities Index (Hui®): Population Reference Statistics
2013
-
Impact of Major Clinical Events on Utilities in the Context of Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) Treated with Dialysis
2013
-
Measuring Pros That Matter to Bariatric and Body Contouring Surgery: The Body-Q
2013
-
Multinational Consistency of a Discrete Choice Model in Quantifying Health States for the Extended 5-Level EQ-5D
2013
-
Population Based Utilization of Radiation Therapy by a Canadian Breast Cancer Cohort
2013
-
Psychoactive Drug Use, Polypharmacy and Co-Morbidities in Newly Diagnosed Patients with Pervasive Development Disorder in the Province of Quebec
2013
-
RESPIRATORY SYNCYTIAL VIRUS HOSPITALIZATION IN INFANTS WITH CONGENITAL AIRWAY ANOMALIES IN THE CANADIAN REGISTRY OF SYNAGIS (R) (CARESS) FOLLOWING PROPHYLAXIS (2005-2012)
2013
-
RESPIRATORY SYNCYTIAL VIRUS HOSPITALIZATIONS IN THE CANADIAN REGISTRY FOR SYNAGIS (CARESS)
2013
-
Are canadians different from americans in stated preferences for health? valuing EQ-5D-5L health states using discrete choice experiments
2013
-
CAN INDIVIDUAL HEALTH TECHNOLOGIES IMPROVE OVERALL CHRONIC DISEASE MANAGEMENT?
2013
-
COMPARING EQ-5D VALUATION STUDIES: A SYSTEMATIC REVIEW AND METHODOLOGICAL REPORTING CHECKLIST
2013
-
Cost-Effectiveness Of Eml4-Alk Fusion Testing In Combination With Crizotinib Treatment For Patients With Advanced Non-Small Cell Lung Cancer Living In Ontario
2013
-
Cost-effectiveness of ticagrelor versus generic clopidogrel in patients with acute coronary syndromes in Canada
2013
-
DEVELOPMENT OF THE 6-10 YEAR INTERVIEWER-ADMINISTERED VERSION OF THE ASTHMA CONTROL QUESTIONNAIRE (ACQ-IA) IN SPANISH FOR GUATEMALA AND PERU
2013
-
Excite – A New Collaborative Model Of Pre-Market Evaluation Of Health Technologies
2013
-
HEALTH UTILITIES INDEX (R) : EXTENDING THE AGE RANGE TO PRE-SCHOOLERS
2013
-
Harmonization Of Health Technology Assessement And Regulatory Processes And Evidentiary Requirements For Drugs And Devices: Opportunities And Challenges
2013
-
How can we use discrete event simulation to improve access to health care: an assessment of increasing access to care for children with medically refractory epilepsy
2013
-
Impact of multiple treatment comparison meta-analysis on value of information evaluations: a case study of pharmacotherapies for chronic obstructive pulmonary diseases
2013
-
Modelling drug class effects in bayesian multiple treatment comparison meta-analysis: Applications in early and advanced parkinson's disease
2013
-
Psychometric Development Of A New Pro Instrument: The Face-Q Scales For Facelift Patients
2013
-
Reliability and validity of current perception threshold test in mechanical neck disorder
2013
-
Responsiveness Of The Face-Q: A New Pro For Facial Aesthetic Paitents
2013
-
Rsv Hospitalization In Infants With Neuromuscular Disease In The Canadian Registry Of Synagis® (Caress) Following Prophylaxis (2005-2012)
2013
-
Systematic review of cost-effectiveness analyses of dabigatran versus warfarin for atrial fibrillation across different health care systems
2013
-
The effects of excluding treatments from network meta-analysis
2013
-
Underestimation of uncertainties in health utilities dervied from mapping algorithms involving health-related quality of life measures: statistical explanations and potential remedies
2013
-
Valuing EQ-5D-5L: Can latent utilities derived from a discrete choice model be transformed to health utilities derived from time trade-off tasks?
2013
-
Why are the findings of cost-effectiveness analyses of biologic treatment for rheumatoid arthritis so different?
2013
-
Why are the findings of indirect comparisons of boceprevir and telaprevir for hepatitis C infection different? A methodological review
2013
-
CHARACTERISTICS OF THE ABORIGINAL PEOPLE WITH DIABETES IN THE SOUTH-WESTERN OF ONTARIO, CANADA
2012
-
CL3 Calibrating Bayesian Multiple Treatment Comparison Meta-Analysis With Multiple Cost-Effectiveness Acceptability Curves
2012
-
PCN110 Differences in Health-Related Quality of Life Between Children Treated for Acute Lymphoblastic Leukemia (ALL) on Dana Farber Cancer Institute (DFCI) Protocols
2012
-
PDB34 Economic Evaluation of Treating Diabetes Patients According to Guidelines in South-Western Ontario, Canada
2012
-
PDB77 Characteristics of Patients With Diabetes in Southwestern Ontario, Canada
2012
-
PHP174 Physical Activity Matters: The Associations Between Body Mass Index, Physical Activity and Health-Realted Quality-of-Life Trajectories Over 10 Years
2012
-
PHP202 Bridging the Gap Between Institutional Levels Using Systems Analysis
2012
-
PMS6 Anti-Tumour Necrosis Factor (TNF) Drugs for the Treatment of Psoriatic Arthritis (PsA)
2012
-
PMS60 The Time Horizon Matters: Exploratory Results Varying the Time Horizon in Time Trade-Off and Standard Gamble Utility Elicitation
2012
-
PRM148 Sample Size and Power Considerations in Network Meta-Analysis
2012
-
PRM6 Transferability of Indirect Cost of Chronic Disease: A Systematic Review and Meta-Analysis
2012
-
PRS39 Preference and Willingness to Pay for a Treatment of Pulmonary Arterial Hypertension
2012
-
PSU11 Medical Costs Comparison Between Internal Fixation and Arthoplasty in Patients With Hip Femoral Neck Fractures
2012
-
EMPIRICAL EXAMINATION OF STARTING POINT BIAS WITH THE BIDDING GAME IN A WILLINGNESS-TO-PAY ANALYSIS
2012
-
MO4 Economic Evaluation of Treatment Strategies for Late-Presentation Acute Ischemic Stroke
2012
-
PCV5 Intra-Arterial Thrombolysis Versus Standard Treatment or Intravenous Thrombolysis in Adults with Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
2012
-
PIH39 Eliciting Preferences to the EQ-5D-5L Health States: Discrete Choice Experiment or Multiprofile Case of Best-Worst Scaling
2012
-
PIH56 Measuring Quality of Life in Facial Aesthetic Patients: Field-Testing of a New Modular System (the FACE-Q)
2012
-
PIN30 Economic Evaluation of a Cluster Randomized Controlled Trial of an Influenza Immunization Program Directed at Healthy Children
2012
-
PMD25 Comparison of Statistical Methods Used to Model Health Care Costs by Dialysis Modality in the Treatment of Kidney Failure
2012
-
PMD3 Does Current Perception Threshold Test Can Differentiate Categories of Mechanical Neck Disorder?
2012
-
PMD8 Efficacy of Systemic Hyperbaric Oxygen Therapy for Non-Healing Diabetic Ulcers of the Lower Limb: Systematic Review and Meta-Analysis
2012
-
PMS85 Why the Findings of Published Rheumatoid Arthritis Multiple Treatment Comparisons are So Different - An Overview of Recurrent Methodological Shortcomings
2012
-
PMS90 the Influence of ‘Weak Links' on Comparative Treatment Effects in Multiple Treatment Comparison Meta-Analysis: A Simulation Study
2012
-
PRM28 Physicians as Pseudo-Agents in a Hospital Emergency Department Discrete Event Simulation
2012
-
PRS52 The Stability of Additive Treatment Effects in Multiple Treatment Comparison Meta-Analysis: a Simulation Study
2012
-
PSY65 Meta-Analysis of Health-Related Quality of Life Outcomes – Methods for Enhancing Interpretability of Findings
2012
-
A COMPARATIVE STUDY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PROPHYLAXIS IN PREMATURE INFANTS
2011
-
CARESS: THE CANADIAN REGISTRY OF SYNAGIS (2005-2010)
2011
-
PCN112 Cost-Utility of Treatment for Acute Lymphoblastic Leukemia (ALL) in Childhood
2011
-
PCN127 Health State Utility Assessment for Breast Cancer
2011
-
PCN175 Reimbursement of Anticancer Drugs in Canada: What Can We Learn from the Nice New Appraisal Process for Life-Extending End-of-Life Treatments?
2011
-
PCV110 Health-Related Quality of Life After Venous Thromboembolism
2011
-
PCV50 Hospital Costs Associated with Atrial Fibrillation in Canada
2011
-
PHP158 Determining the Monetary Value of a Quality-Adjusted Life Year (QALY): Systematic Review of the Evidence
2011
-
PMD34 Cost Effectivness of Ambulatory Cardiac Monitor versus Holter
2011
-
PMD86 A Systematic Review of Economic Evaluations Conducted for Assessment of Genetic Testing Technologies
2011
-
PMH26 Direct Cost of Schizophrenia in Quebec, Canada: An Incidence-Based Microsimulation Monte-Carlo Markov Model
2011
-
PMS22 The Burden of Illness of Osteoporosis in Canada
2011
-
PSY41 Health Status and Health-Related Quality of Life Reported by Females with Bleeding Disorders from the Canadian National Haemophilia Registry
2011
-
RESPIRATORY SYNCYTIAL VIRUS (RSV) PROPHYLAXIS IN SPECIAL POPULATIONS
2011
-
RESPIRATORY SYNCYTIAL VIRUS HOSPITALIZATIONS IN THE CANADIAN REGISTRY FOR SYNAGIS (CARESS)
2011
-
PDB76 DESIGNING A SERVICE FRAMEWORK FOR ELECTRONIC PERSONAL HEALTH RECORDS: A PATIENT-CENTRED APPROACH
2011
-
PIN34 INTRANASAL LIVE ATTENUATED (LAIV) VERSUS INJECTABLE INACTIVATED (TIV) INFLUENZA VACCINE FOR CHILDREN AND ADOLESCENTS: A CANADIAN COST EFFECTIVENESS ANALYSIS
2011
-
PMD19 COST-EFFECTIVENESS OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE MUTATION TESTING IN THE SELECTION OF FIRST-LINE THERAPY FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER IN ONTARIO
2011
-
PMD25 THE COST-UTILITY AND VALUE OF INFORMATION OF TRANSCATHETER AORTIC VALVE IMPLANTATION COMPARED TO STANDARD MANAGEMENT AND SURGICAL AORTIC VALVE REPLACEMENT IN PATIENTS WITH SEVERE SYMPTOMATIC AORTIC VALVE STENOSIS
2011
-
PRM29 METHODOLOGICAL DIFFERENCES IN EQ-5D SCORING SYSTEMS: A SYSTEMATIC REVIEW AND ANALYSIS
2011
-
PSY23 ECONOMIC EVALUATION OF ERYTHROPOIESIS STIMULATING AGENTS IN CRITICALLY ILL TRAUMA PATIENTS
2011
-
PSY48 A WORKPLACE HEALTH PROGRAM FOR BRITISH COLUMBIA PUBLIC SERVICE AGENCY (CANADA)
2011
-
PUK6 LOW-MOLECULAR-WEIGHT HEPARIN IN CHRONIC HEMODIALYSIS PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
2011
-
CARESS: THE CANADIAN REGISTRY OF SYNAGIS (2006-2009)
2010
-
PDB35 COST-CONSEQUENCE ANALYSIS OF CSII VS. MDI:A CANADIAN PERSPECTIVE
2010
-
PMC31 CONSTRUCTION OF PRIMARY HUI3 PERSON-MEAN UTILITY SCORING FUNCTION
2010
-
PMS21 THE ACUTE CARE COSTS OF OSTEOPOROSIS-RELATED FRACTURES IN CANADA
2010
-
PRS42 EFFECTS OF ASTHMA MANAGEMENT, SOCIOECONOMIC STATUS AND MEDICATION INSURANCE CHARACTERISTICS ON EXACERBATION FREQUENCY IN CHILDREN WITH ASTHMA
2010
-
RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS IN SPECIAL POPULATIONS
2010
-
HEALTH STATUS, PHYSICIAN, DAY PROCEDURES AND HOPITALIZATION COSTS ASSOCIATED WITH RHEUMATOID-ARTHRITIS IN ONTARIO
2010
-
PCN143 COST-EFFECTIVENESS OBSERVATIONS AND ONCOLOGY DRUG REIMBURSEMENT RECOMMENDATIONS IN CANADA BY THE JOINT ONCOLOGY DRUG REVIEW
2010
-
PCN31 COST COMPARISON OF INPATIENT AND OUTPATIENT HOSPITALBASED SERVICES BETWEEN TWO STRATEGIES FOR TREATMENT OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN A PUBLICLY FUNDED HEALTH CARE SYSTEM
2010
-
PGI26 CANADIAN COST-UTILITY ANALYSIS OF INITIATION AND MAINTENANCE TREATMENT WITH ANTI-TNF DRUGS FOR REFRACTORY CROHN'S DISEASE
2010
-
PMS74 USE OF A DISEASE-SPECIFIC INSTRUMENT IN ECONOMIC EVALUATIONS: MAPPING WOMAC ONTO THE EQ-5D UTILITY INDEX
2010
-
PR4 ARE HEALTH STATES “TIMELESS”? A TEST OF THE UTILITY INDEPENDENCE ASSUMPTION: COMPARING A REPEATED MEASURES DESIGN AND LATENT GROWTH MODELING
2010
-
PRS7 TRIPLE THERAPY FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE
2010
-
PSY30 COST-EFFECTIVENESS OF BARIATRIC SURGICAL PROCEDURES VERSUS NO TREATMENT FOR MORBID OBESITY
2010
-
UT3 RELIABILITY OF HEALTH UTILITIES INDEX (HUI) SCORES: PATIENT AND PARENT INTER-RATER AGREEMENT ACROSS TWO CLINICAL TRIALS OF TREATMENT FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN CHILDHOOD
2010
-
UTILIZING HEALTH SURVEY AND ADMINISTRATIVE DATA TO ESTIMATE THE BURDEN OF OSTEO-ARTHRITIS IN ONTARIO
2010
-
DB1 USING POPULATION-BASED ESTIMATES FOR DISEASE MODELING: POTENTIAL BIAS COMPARED TO USING DISEASE-SPECIFIC DEATH AND COMPLICATION RISK ESTIMATES
2009
-
MC6 SCHIZOPHRENIA MODELING: MARKOV MODEL WITH MONTE-CARLO MICROSIMULATION
2009
-
MO3 R THERE ANY DIFFERENCES BETWEEN EXCEL AND R? COMPARISON OF ICER ESTIMATES AND CEACS OBTAINED FROM A MODEL IMPLEMENTED IN MICROSOFT EXCEL AND R
2009
-
PCN130 HEALTH UTILITIES OF CHILDREN TREATED FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN DFCI 95-01 RANDOMIZED CLINICAL TRIAL
2009
-
PCN31 A DESCRIPTIVE ANALYSIS OF THE ASSOCIATION BETWEEN BREAST CANCER RISK, BONE MINERAL DENSITY AND FRACTURES IN POST-MENOPAUSAL WOMEN IN THE CANADIAN MULTICENTRE OSTEOPOROSIS STUDY
2009
-
PCV110 COST-EFFECTIVENESS ANALYSIS OF ENOXAPARIN FOR EXTENDED THROMBOPROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) AFTER ELECTIVE TOTAL HIP REPLACEMENT (THR) SURGERY
2009
-
PDB21 WHO ARE THEY FOOLING?: COST OF DISEASE OR COMPLICATIONS CAN SIGNIFICANTLY BIAS ESTIMATES UNLESS CONTROL (NON-DISEASED) COSTS ARE NOT ALSO ACCOUNTED FOR IN THE ANALYSIS
2009
-
PG14 SYSTEMATIC REVIEW: THE CLINICAL EFFECTIVENESS OF ANTI-TNFALPHA DRUGS IN ADULTS WITH REFRACTORY CROHN'S DISEASE
2009
-
PHP80 CLINICAL EFFECTIVENESS OF PORTABLE ULTRASOUND IN SMALL EMERGENCY DEPARTMENTS: A SYSTEMATIC REVIEW
2009
-
PMC35 SCHIZOPHRENIA MODELING: MARKOV MODEL WITH MONTE-CARLO MICROSIMULATION
2009
-
PMH18 SCHIZOPHRENIA MODELING: FACTORS ASSOCIATED WITH THE RISK OF BEING IN A SPECIFIC DISEASE STATE
2009
-
PMH2 SCHIZOPHRENIA MODELING: FACTORS ASSOCIATED WITH THE RISK OF BEING IN A SPECIFIC DISEASE STATE
2009
-
PND31 HEALTH UTILITY SCORES ASSOCIATED WITH A HYPOTHETICAL MODERATE ALZHEIMER'S DISEASE HEALTH STATE: A CANADIAN SURVEY OF THE GENERAL PUBLIC
2009
-
PND46 A SYSTEMATIC REVIEW AND META-ANALYSIS OF INTRAVENOUS IMMUNOGLOBULIN FOR THE TREATMENT OF CIDP
2009
-
PND47 ASSESSING CANADIANS' WILLINGNESS-TO-PAY FOR ALZHEIMER'S DISEASE MEDICATIONS
2009
-
PND48 SUPPORT FOR PROVIDING UNRESTRICTED ACCESS TO AN ALZHEIMER'S DISEASE MEDICATION IN CANADA: RESULTS FROM A STUDY OF THE GENERAL POPULATION
2009
-
PSY18 THE BURDEN OF OBESITY IN ONTARIO
2009
-
PSY30 COST-UTILITY OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) COMPARED WITH CORTICOSTEROIDS FOR THE TREATMENT OF CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) IN CANADA
2009
-
PSY38 ELICITING HEALTH STATE UTILITIES FOR IMMUNE (IDIOPATHIC) THROMBOCYTOPENIC PURPURA: RESULTS OF A GENERAL PUBLIC BASED TIME TRADE-OFF SURVEY
2009
-
PSY42 BLEEDING DISORDERS, MENORRHAGIA AND IRON DEFICIENCY: AN EXAMINATION OF QUALITY OF LIFE
2009
-
HT2 HEALTH TECHNOLOGY ASSESSMENT – A COMPREHENSIVE FRAMEWORK FOR EVIDENCE-BASED RECOMMENDATIONS IN ONTARIO
2009
-
PCN68 COST-EFFECTIVENESS OF CETUXIMAB (ERBITUXTM) FOR THE FIRST LINE TREATMENT OF SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) IN CANADA
2009
-
PGI6 COST EFFECTIVENESS ANALYSIS OF ANTI-TNF-ALPHA; DRUGS FOR REFRACTORY ULCERATIVE COLITIS
2009
-
PIH11 ECONOMIC EVALUATION ALONGSIDE THE CAFFEINE FOR APNEA OF PREMATURITY (CAP) TRIAL: SHORT TERM OUTCOMES
2009
-
PIH56 CARESS: THE CANADIAN REGISTRY OF SYNAGIS, SUMMARY OF 2006–2008 RSV SEASONS
2009
-
PMC62 ASSESSING THE QUALITY OF CONJOINT ANALYSIS APPLICATIONS IN HEALTH: A PILOT EVALUATION OF THE ISPOR CHECKLIST FOR GOOD RESEARCH PRACTICE IN CONJOINT ANALYSIS
2009
-
PMS43 IS THE HEALTH UTILITIES INDEX VALID AND RESPONSIVE IN ASSESSING PATIENTS WITH ANKYLOSING SPONDYLITIS?
2009
-
PMS45 EXTENSION FROM INPATIENTS TO OUTPATIENTS: PERFORMANCE OF THE OXFORD KNEE SCORE IN MEASURING HEALTH OUTCOMES IN PATIENTS WITH KNEE OSTEOARTHRITIS
2009
-
PND26 UTILITIES FOR MODERATE ALZHEIMER'S DISEASE: RESULTS FROM A SURVEY OF THE GENERAL PUBLIC IN CANADA
2009
-
PSY9 USING UTILIZATION RECORDS TO ESTIMATE THE BURDEN OF OBESITY IN ADULTS LIVING IN ONTARIO
2009
-
QL3 ESTIMATION OF UTILITY VALUES FOR DIABETESXD-RELATED COMPLICATIONS ON QUALITY OF LIFE FOR PATIENTS WITH TYPE-2 DIABETES IN ONTARIO, CANADA
2009
-
CASE2 DOTECHNOLOGY EVALUATIONS BASED ON EVIDENCE FROM CONDITIONAL FUNDING LEAD TO AN INCREASE IN POLICY FORMATION?: FINDINGS FROM, AND IMPLICATIONS OF, ONTARIO'S EVIDENCE-BASED HTA PROCESS
2008
-
PCV93 FACTORS DETERMINING UTILITY MEASURED WITHTHE EQ-5D IN PATIENTS WITH A TRIAL FIBRILLATION
2008
-
PMC60 CONSISTENTLY ESTIMATING RISK DIFFERENCE IN A JURISDICTION OF INTEREST: ODDS SOLUTION TO RELATIVE RISK FALLACIES
2008
-
PRS21 CAN ASTHMA QUALITY OF LIFE QUESTIONNAIRE (AQLQ) DATA FROM DIFFERENT COUNTRIES BE COMBINED FOR ANALYSES?
2008
-
PRS22 ARE THE MEASUREMENT PROPERTIES OF THE ASTHMA QUALITY OF LIFE QUESTIONNAIRE (AQLQ) CONSISTENT ACROSS LANGUAGES?
2008
-
CASE 2 DRUG ELUTING STENTS—AN EXAMPLE OFTHETRANSITION FROM EVIDENCETO POLICYTHROUGHTHE ONTARIO COMPREHENSIVE APPROACHTOTHE DIFFUSION OF HEALTHTECHNOLOGIES
2008
-
DH3 THE IMPACT OF DRUG VINTAGE ON PATIENT SURVIVAL: A PATIENT-LEVEL APPROACH USING QUEBEC'S PROVINCIAL HEALTH PLAN DATA
2008
-
OM2 USINGVALUE OF INFORMATION METHODOLOGYTO DETERMINE THE SAMPLE SIZE FOR A RANDOMIZED CLINICAL TRIAL FROM AN INDUSTRY PERSPECTIVE
2008
-
PCN58 A COST UTILITY ANALYSIS OF ERLOTINIB IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
2008
-
PCN72 DISABILITY AND HEALTH-RELATED QUALITY OF LIFE IN LONG-TERM SURVIVORS OF CANCER IN CHILDHOOD IN BRAZIL: AN ASSESSMENT OF THE CONSTRUCT VALIDITY OF THE HEALTH UTILITIES INDEX (HUI3)
2008
-
PCN73 COMPARISON OF SURVIVAL QUALITY FROM TWO TREATMENT STRATEGIES FORACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN CHILDHOOD: DANA-FARBER CANCER INSTITUTE (DFCI) AND BERLIN-FRANKFURT-MONSTER (BFM)
2008
-
PCN93 THREE SCIENTIFIC PARADIGMS IN HEALTH TECHNOLOGY ASSESSMENT: EXPERIENCES OF THE COMMITTEE TO EVALUATE DRUGS IN ONTARIO, CANADA
2008
-
PCV12 METHODS FOR INDIVIDUALIZING THE BENEFIT AND HARM OF WARFARIN
2008
-
PCV53 DRUG-ELUTING STENTS FROM A MEDICARE PAYER PERSPECTIVE: COST-UTILITY ANALYSIS WITH 4-YEAR CLINICAL META-ANALYSIS DATA
2008
-
PCV67 RESPONSIVENESS OF PROXY-RATED PREFERENCE-BASED MEASURES OF HEALTH-RELATED QUALITY OF LIFE
2008
-
PGI7 COST EFFECTIVENESS ANALYSIS OF HELICOBACTER PYLORI SCREENING IN PREVENTION OF GASTRIC CANCER IN CHINESE
2008
-
PHP25 TOWARD HIGH PERFORMANCE ‘PHARMACARE’ SYSTEMS: A REVIEW OF EXPERIENCES IN SEVEN COUNTRIES
2008
-
PHP74 THE CADTH GUIDELINES FORTHE ECONOMIC EVALUATION OF HEALTH TECHNOLOGIES: DO CURRENT CANADIAN ECONOMIC EVALUATIONS PASS THE TEST?
2008
-
PIH11 IMPACT OF THE RISK SCORING MODEL ON THE COST-EFFECTIVENESS OF PALIVIZUMAB FOR RESPIRATORY SYNCYTIALVIRUS PROPHYLAXIS IN PREMATURE INFANTS WITH A GESTATIONAL AGE OF 32-35 WEEKS IN CANADA
2008
-
PIH22 CARESS: THE CANADIAN REGISTRY OF SYNAGIS(®)
2008
-
PM3 THEVALIDITY AND RELIABILITY OF A PARENT-CHILD DYAD APPROACHTO UTILITY AND QUALITY-OF-LIFE ASSESSMENT IN CHILDREN
2008
-
PMC15 DETERMINING THE MECHANISM OF MISSING DATA IN INCOMPLETE DATASETS
2008
-
PMH65 EFFECT OF PRIOR AUTHORIZATION ON ANTIPSYCHOTIC DRUG USE IN LONG-TERM CARE: POPULATION-BASED NATURAL EXPERIMENT
2008
-
PMS34 ATWO-YEAR EVALUATION OF HEALTH OUTCOMES IN OSTEOARTHRITIS PATIENTS AFTERTOTAL KNEE REPLACEMENT
2008
-
PMS7 TREATMENT OF DISPLACED FEMORAL NECK FRACTURES IN THE ELDERLYA COST BENEFIT ANALYSIS
2008
-
PR1 VARIABILITY OF HEALTH UTILITIES INDEX MARK 3 (HUI3) MEASUREMENTS DURINGTREATMENT FOR ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDHOOD
2008
-
Evidence-Based Medicine in China
2008
-
PAR32 INVESTIGATION OF RESPONSE SHIFT IN HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS UNDERGOINGTOTAL KNEE REPLACEMENT
2007
-
PCN76 COMPARISON OF PHYSICIAN AND PATIENT PREFERENCES FOR COLORECTAL CANCER SCREENING USING A DISCRETE CHOICE EXPERIMENT
2007
-
PCN45 A PRACTICAL AND USEFUL COMBINATION OF MEASURES FOR ASSESSING THE COST-UTILITY OF TWO MAJOR TREATMENT STRATEGIES FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN CHILDHOOD: RESOURCE INTENSITY WEIGHTS (RIWS) AND THE HEALTH UTILITIES INDEX (HUI)
2007
-
PND27 DETECTION OF DIFFERENTIAL ITEM FUNCTIONING BETWEEN ENGLISH AND CHINESE VERSIONS OF THE PDQ-8
2007
-
PST3 THE IMPACT OF WIDESPREAD ACCESS TO ORGANIZED STROKE CARE IN CANADA
2007
-
PAR11 ARE THEY MEASURABLE? A STUDY ON ELICITING INDIRECT AND INTANGIBLE COSTS OF KNEE OSTEOARTHRITIS USING HUMAN CAPITAL APPROACH AND WILLINGNESS-TO-PAY IN MULTIETHNIC ASIAN POPULATION IN SINGAPORE
2006
-
PCN70 RELIABILITY AND VALIDITY OF HEALTH UTILITIES INDEX (HUI) SCORES FOR SURVIVORS OF BRAIN TUMORS IN CHILDHOOD: AGREEMENT BETWEEN PATIENTS AND PARENTS
2006
-
PCV55 ECONOMIC EVALUATION OF DRUG ELUTING STENTS: COST-UTILITY ANALYSIS
2006
-
PCV77 DISCRETE-EVENT-SIMULATION AN APPROACH THAT CHALLENGES TRADITIONAL MODELING METHODS? AN ILLUSTRATION USING DRUG-ELUTING STENTS
2006
-
PMH11 RATIONAL CHOICE OF TREATMENT STRATEGY IN MODERATE TO SEVERE ALZHEIMER'S DISEASE PATIENTS LIVING IN CANADA
2006
-
PRS13 USING PATIENT DESCRIPTORS TO DEVELOP A PRO MEASUREMENT STRATEGY FOR CLINICAL TRIALS: EVALUATING THE COPD PATIENT'S EXPERIENCE OF DYSPNEA
2006
-
PRS16 MEASURING THE IMPACT OF COPD ON PATIIENTS' LIVES IN AN INTERNATIONAL STUDY
2006
-
CE4 COST EFFECTIVENESS OF DRUG ELUTING STENTS (DES) COMPARED TO BARE METAL STENTS (BMS) USING “REAL WORLD” DATA
2006
-
PAR15 PRELIMINARY INVESTIGATION OF THE DISCRIMINATORY CAPACITY OF MEASURES OF LOW INTENSITY SYMPTOM STATE-ATTAINMENT USING THE WOMAC PAIN SUBSCALE SCORE IN PATIENTS TREATED WITH HYLAN G-F 20 FOR KNEE OSTEOARTHRITIS
2006
-
PAS3 ECONOMIC EVALUATION OF SYMBICORT® (BUDESONIDE/FORMOTEROL) SINGLE-INHALER MAINTENANCE AND RELIEVERTHERAPY (SMART) IN ASTHMA
2006
-
PCN26 INTER-RATERAGREEMENT OF HUI3 UTILITY SCORES FOR PATIENTS AT FOUR PHASES OF THERAPY FOR ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDHOOD: PARENT VERSUS CLINICIAN ASSESSMENT
2006
-
PCN27 HEALTH STATUS MEASURES AS PREDICTORS OF MORTALITY AMONG ADULTS WITH BRAIN TUMORS
2006
-
PDB10 MODELLING LIFETIME HEATLH CARE COSTS AND CONSEQUENCES OF A NURSE-LED MULTIFACETED INTERVENTION TO IMPROVE THE MANAGEMENT OF PATIENTS WITH DIABETES: RESULTS FROM A COMPUTERIZED SIMULATION MODEL
2006
-
PDB19 IMPROVING THE MEASUREMENT OF THE COST OF DIABETES-RELATED COMPLICATIONS: RESULTS FROM A LARGE PROSPECTIVE COHORT STUDY
2006
-
PEY8 ECONOMIC EVALUATION OF EARLY TREATMENT FOR PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA
2006
-
PMC1 TRANSFERABILITY OF ECONOMIC EVALUATIONS: CAN RESULTS FROM ONE GEOGRAPHIC AREA BE USED TO HELP INFORM HEALTH CARE DECISION MAKING IN ANOTHER?
2006
-
PMC13 APPLYING EXPECTANCY-VALUE MODEL TO UNDERSTAND HEALTH PREFERENCE-AN EXPLORATORY STUDY
2006
-
PSU1 COST-UTILTY OF ELECTIVE ENDOVASCULAR REPAIR (EVAR) COMPARED TO OPEN SURGICAL REPAIR (OSR) OF ABDOMINAL AORTIC ANEURYSMS (AAA)
2006
-
PAR10 ARE THEY RELEVANT? A CRITICAL EVALUATION OF THE INTERNATIONAL CLASSIFICATION OF FUNCTIONING, DISABILITY AND HEALTH CORE SETS FOR OSTEOARTHRITIS FROM THE PERSPECTIVE OF PATIENTS WITH KNEE OSTEOARTHRITIS IN SINGAPORE
2005
-
PAR16 POTENTIAL PROBLEMS IN USING RCT DATA TO ESTIMATE COST-EFFECTIVENESS: RESULTS FROM AN ANALYSIS OF ETANERCEPT USE IN RHEUMATOID ARTHRITIS
2005
-
PAR9 A MODEL TO ESTIMATE HEALTH UTILITIES INDEX MARK 3 UTILITY SCORES FROM WOMAC INDEX SCORES IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE
2005
-
PDB57 TREATMENT SATISFACTION AND QUALITY OF LIFE WITH AN EARLY INSULINIZATION STRATEGYWITH INSULIN GLARGINE COMPARED TO AN ADJUSTED ORAL THERAPY IN THE MANAGEMENT OF TYPE-2 DIABETES: THE CANADIAN INSIGHT STUDY
2005
-
PMD1 COST ANALYSIS OF MANAGEMENT STRATEGIES FOR CLOSED AND OPEN GRADE ITIBIAL SHAFT FRACTURES
2005
-
PMH42 COMPARISON OF SSRI AND SNRI TREATMENT FOR DEPRESSION IN PRIMARY CARE: A NATURALISTIC STUDY
2005
-
PST10 THE METHODOLOGY BEHIND A PROSPECTIVE, OBSERVATIONAL STUDY OF THE ECONOMIC BURDEN OF ISCHEMIC STROKE
2005
-
PCN23 RELIABILITY OF SPANISH-LANGUAGE HUI MEASUREMENTS IN SURVIVORS OF CANCER IN CHILDHOOD:AGREEMENT BETWEEN PATIENTS, PARENTS, AND PHYSICIANS
2005
-
PCN25 RELIABILITY AND VALIDITY OF BRAZILIAN PORTUGUESE HEALTH UTILITIES INDEX (HUI) QUESTIONNAIRES FOR ASSESSING THE HEALTH STATUS OF SURVIVORS OF CHILDHOOD CANCER
2005
-
PCV26 THE COST-EFFECTIVENESS OF EXTENDED ANTITHROMBOTIC PROPHYLAXIS FOLLOWING TOTAL HIP ARTHROPLASTY
2004
-
PCV4 FIRST ANALYSIS OF CLINICAL SIGNIFICANT INTERACTIONS IN HIGH-RISK CARDIOVSCULAR PATIENTS ENROLLED INTO HOPE-TOO TRIAL IN SLOVAKIA IN THE THIRD YEAR OF TRIAL PARTICIPATION
2004
-
PIN26 VALIDATION OF 5-ITEM INSTRUMENT FOR ASSESSING SYMPTOM SEVERITY IN PATIENTS WITH ACUTE BACTERIAL SINUSITIS
2004
-
PCN22 THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE CORE QUESTIONNAIRE (EORTC QLQ-C30): VALIDATION OF ENGLISH VERSION IN SINGAPORE
2004
-
PCN26 ARE HEALTH STATES “TIMELESS”? A TEST OF THE UTILITY INDEPENDENCE ASSUMPTION USING A REPEATED MEASURES DESIGN
2004
-
PGI9 RESPONSIVENESS TO CHANGE AND ENGLISH LANGUAGE VALIDATION OF THE WPAI-GERD QUESTIONNAIRE-RESULTS FROM A CANADIAN STUDY
2004
-
SC1 PATIENT PREFERENCES FOR COLORECTAL CANCER (CRC) SCREENING STRATEGIES
2004
-
CE1 COST-EFFECTIVENESS MODEL OF RECOMBINANT HUMAN CHORIONIC GONADOTROPIN (R-HCG) VERSUS URINARY HCG (U-HCG) FOR ASSISTED REPRODUCTIVE TECHNIQUES (ART) IN THE USA
2003
-
Quality of life (QOL) differentiation analysis in patients undergoing controlled ovarian stimulation (COS) with two different preparations of recombinant human follicle-stimulating hormone (r-hFSH)
2003
-
PCHI5: AGREEMENT OF HEALTH UTILITIES INDEX SCORES AMONG SURVIVORS OF CANCER IN CHILDHOOD THEIR PARENTS AND THEIR DOCTORS IN URUGUAY
2003
-
PGS6: THE COST-EFFECTIVENESS OF ALTERNATIVE STRATEGIES IN THE MANAGEMENT OF PATIENTS WITH UNINVESTIGATED DYSPEPSIA (UD): COMPARING THE CANDYS APPROACH TO EMPIRICAL ANTISECRETORY THERAPY AND PROMPT ENDOSCOPY
2003
-
PIN6: IMPACT OF CHANGES IN REIMBURSEMENT POLICY ON ANTIBIOTIC RESISTANCE
2003
-
PIN9: IMPACT OF CHANGES IN REIMBURSEMENT POLICY ON ANTIBIOTIC USE AND EXPENDITURES
2003
-
Is there any relationship between compliance and HRQoL in patients with heart failure?
2002
-
PCV37 DOES COMPLIANCE WITH ACE-I, DIGOXIN AND SPIRONOLACTONE INFLUENCE THE TIME TO EVENT IN PATIENTS WITH HEART FAILURE?
2002
-
PCV47 THE ASSESSMENT OF THE INFLUENCE OF AN EDUCATIONAL INTERVENTION ON PATIENT IMPORTANT OUTCOMES INCLUDING HEALTH RELATED QUALITY OF LIFE (HRQOL) AND MORTALITY USING A TIME-TO-EVENT SURVIVAL ANALYSIS IN PATIENTS WITH HEART FAILURE
2002
-
The impact of an educational intervention on multiple health realted quality of life measures in patients with heart failure (HF)
2002
-
A Systematic Review and Quality Assessment of Cardiovascular Disease-Specific Health-Related Quality-of-Life Instruments Part I: Instrument Development and Content Validity.
27:1130-1148.
2024
-
Health Fluctuations in Dementia and its Impact on the Assessment of Health-Related Quality of Life Using the EQ-5D-5L.
27:1092-1099.
2024
-
The Inflation Reduction Act: An Opportunity to Accelerate Confidence in Real-World Evidence in the United States.
27:999-1002.
2024
-
Development of a Value Assessment Framework for Pediatric Health Technologies Using Multicriteria Decision Analysis: Expanding the Value Lens for Funding Decision Making.
27:879-888.
2024
-
Do Quality-Adjusted Life Years Discriminate Against the Elderly? An Empirical Analysis of Published Cost-Effectiveness Analyses.
27:706-712.
2024
-
PCR180 Measuring and Valuing Child Health in Canada.
27:s329.
2024
-
PCR42 Health State Utilities in Duchenne Muscular Dystrophy (DMD): A Longitudinal Study Using the EQ5D and Health Utilities Index (HUI).
27:S303-S303.
2024
-
Validation of China Health-Related Outcomes Measures-Cardiovascular Disease.
27:490-499.
2024
-
Scoring the Value Assessment Framework for China: A Factorial Survey.
27:330-339.
2024
-
EE390 Optimizing the Use of Risk Factors to Guide the Cost-Effective Use of Palivizumab Prophylaxis Against Severe Respiratory Syncytial Virus Infection in Korean Infants Born 32–35 Weeks’ Gestational Age.
26:S125-S125.
2023
-
EE542 Assessment of the Cost-Effectiveness of Risk Factor Guided Prophylaxis with Palivizumab for the Prevention of Severe Respiratory Syncytial Virus Infection in Colombian Infants Born at 32–35 Weeks’ Gestational Age.
26:S156-S156.
2023
-
Real-World Cost-Effectiveness of Pulmonary Vein Isolation for Atrial Fibrillation: A Target Trial Approach.
26:1721-1729.
2023
-
Whose Time Trade-Off Should Be Used? Anchoring Discrete Choice Experiment Latent Utilities in Health State Valuation.
26:1405-1412.
2023
-
Resurrecting Multiattribute Utility Function: Developing a Value Set for Health Utility for Glaucoma.
26:1249-1257.
2023
-
P31 The Association between Patient- and Caregiver-Reported Utility Values in Duchenne Muscular Dystrophy (DMD).
26:S7-S7.
2023
-
PCR230 Estimating Utility Values Using the Duchenne Muscular Dystrophy-Quality of Life Measure (DMD-QOL): A New Preference-Based Measure for Duchenne Muscular Dystrophy.
26:S355-S355.
2023
-
Modeling Tiered Pricing Frameworks: A Simulation Approach.
26:351-358.
2023
-
Generic Health-Related Quality of Life Utility Measure for Preschool Children (Health Utilities Preschool): Design, Development, and Properties.
26:251-260.
2023
-
CO107 Clinical Outcomes of Patients With Metastatic Renal Cell Carcinoma (MRCC) With or Without Sarcomatoid Differentiation Treated With Systemic Therapy in Real-World Canadian Setting.
25:S39-S39.
2022
-
CO177 Association Between the Sarcomatoid Status and Percentage of Sarcomatoid on the Clinical Outcomes of Localized Renal Cell Carcinoma Post Nephrectomy.
25:S52-S52.
2022
-
EE417 Development and Application of a New Cost-Utility Model to Assess the Cost-Effectiveness of Palivizumab for the Prevention of Severe Respiratory Syncytial Virus (RSV) Infection in Moderate-to-Late Preterm Infants.
25:S137-S138.
2022
-
EE528 Resource Use and Costs Associated With Computerized Decision Support System for Managing Patients With Atrial Fibrillation.
25:S159-S160.
2022
-
EPH152 Ten-Year Epidemiology, Economic Burden and All-Cause Mortality Among Palmoplantar Pustolosis Patients: A 10-Year Canadian Prevalence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics.
25:S220-S220.
2022
-
EPH192 Ten-Year Epidemiology, Economic Burden and All-Cause Mortality Among Generalized Pustular Psoriasis Patients: A Canadian Prevalence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics.
25:S228-S228.
2022
-
EPH26 Three-Year Epidemiology, Economic Burden and All-Cause Mortality Among Generalized Pustular Psoriasis Patients: A Canadian Incidence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics.
25:S196-S196.
2022
-
EPH46 Three-Year Epidemiology, Economic Burden and All-Cause Mortality Among Palmoplantar Pustolosis Patients: A Canadian Incidence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics.
25:S200-S200.
2022
-
HPR136 The Associations of Prescription Drug Insurance and Cost-Sharing With Drug Use, Health Services Use, and Health – A Systematic Review of Canadian Studies.
25:S257-S257.
2022
-
How Do Treatment Preferences of Patients With Cancer Compare With Those of Oncologists and Family Members? Evidence From a Discrete Choice Experiment in China.
25:1768-1777.
2022
-
EE214 Impact of Depression Relapse on Participant Quality of Life and Costs to the English NHS: Secondary Analysis from the Antler Study on Antidepressant Discontinuation in Well Patients in Primary Care.
25:S375-S375.
2022
-
EE476 Cost-Effectiveness of Emicizumab Prophylaxis in Patients with Hemophilia a without Inhibitors.
25:S428-S428.
2022
-
PCR105 The Impact of Key Health State Transitions on Health-Related Quality of Life (HRQOL) in Duchenne Muscular Dystrophy (DMD): A Qualitative Study.
25:S560-S561.
2022
-
PCR176 Time Trade-Off Utility Values for Health States Characterizing Progressive Muscular Degeneration in Duchenne Muscular Dystrophy (DMD).
25:S574-S574.
2022
-
The (Harsh) Reality of Real-World Data External Comparators for Health Technology Assessment.
25:1253-1256.
2022
-
Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force.
25:869-886.
2022
-
Rasch Analysis of the Michigan Hand Questionnaire.
25:638-646.
2022
-
What Is Value in Health and Healthcare? A Systematic Literature Review of Value Assessment Frameworks.
25:302-317.
2022
-
POSC37 Economic Cost of Treatment in Canada: A Multi-Centre, Retrospective Study.
25:S93-S93.
2022
-
POSC427 Platform Trials: A Path to Efficient Decision Making and Faster Drug Approvals for Health Technology Assessment Bodies.
25:S276-S276.
2022
-
HT3 What is Value? A Systematic Review of Value Assessment Frameworks.
24:S9-S9.
2021
-
SC3 The Drivers of Health State Utilities in Duchenne Muscular Dystrophy (DMD): A Study Using the Health Utilities Index Mark 3 (HUI3).
24:S240-S240.
2021
-
Economic Consequences of Adult Living Kidney Donation: A Systematic Review.
24:592-601.
2021
-
Engaging the Voices of Children: A Scoping Review of How Children and Adolescents Are Involved in the Development of Quality-of-Life–Related Measures.
24:556-567.
2021
-
Rasch Analysis of Patient- and Parent-Reported Outcome Measures in the International Consortium for Health Outcomes Measurement Standard Set for Cleft Lip and Palate.
24:404-412.
2021
-
Acceptability and Validity of the EQ-5D in Patients Living With Dementia.
23:760-767.
2020
-
PNS18 IMPROVING THE APPLICATION OF PUBLISHED HEALTH UTILITIES IN COST-UTILITY ANALYSES: DEVELOPMENT OF THE HEALTH UTILITY APPLICATION TOOL (HAT).
23:S286-S287.
2020
-
Development of System Performance Indicators for Adolescent and Young Adult Cancer Care and Control in Canada.
23:74-88.
2020
-
PCN438 ECONOMIC EVALUATION METHODS IN ONCOLOGY: ONWARDS AND UPWARDS.
22:S521-S521.
2019
-
PDB3 HETEROGENEITY IN RENAL COMPOSITE ENDPOINTS IN CARDIOVASCULAR OUTCOMES TRIALS IN TYPE 2 DIABETES (T2D).
22:S572-S572.
2019
-
PNS278 A REVIEW OF HEALTH TECHNOLOGY ASSESSMENT GUIDELINES ON THE APPROVAL OF BIOSIMILARS.
22:S810-S810.
2019
-
PRO67 UTILITY VALUES FOR HEALTH STATES ASSOCIATED WITH DUCHENNE MUSCULAR DYSTROPHY: A SYSTEMATIC REVIEW.
22:S853-S853.
2019
-
United States Valuation of EQ-5D-5L Health States Using an International Protocol.
22:931-941.
2019
-
Parent Proxy Discrepancy Groups of Quality of Life in Childhood Epilepsy.
22:822-828.
2019
-
PMS52 REAL-WORLD OUTCOMES AND COST OF MANAGEMENT OF OSTEOPOROTIC FRACTURES IN ONTARIO, CANADA.
22:S248-S248.
2019
-
Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease.
21:318-325.
2018
-
Instrument-Defined Estimates of the Minimally Important Difference for EQ-5D-5L Index Scores.
20:644-650.
2017
-
Instrument-Defined Estimates of the Minimally Important Difference for EQ-5D-5L Index Scores.
20:644-650.
2017
-
A Cost-Effectiveness Analysis of Reverse Total Shoulder Arthroplasty versus Hemiarthroplasty for the Management of Complex Proximal Humeral Fractures in the Elderly.
20:404-411.
2017
-
Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report.
19:704-719.
2016
-
Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force.
19:300-315.
2016
-
A Discrete Choice Experiment (Dce) To Elicit Preferences For Attributes Of A Bedside Pharmacogenetic Test – Preliminary Results.
18:A399-A399.
2015
-
Heterogeneity in the Definition of Drug Induced Hypoglycemia in Clinical Trials: A Review.
18:A601-A601.
2015
-
Non-Comparative Trials To Supplement Network Meta-Analyses Using Arm-Specific Meta-Regression: An Application To Combination Therapies In Hiv.
18:A683-A684.
2015
-
Psychiatric Healthcare Utilization and Related Costs In Newly Diagnosed Individuals With Autism Spectrum Disorder (Asd) In Quebec (Canada).
18:A746-A747.
2015
-
The Use of Single-Arm Evidence In The Comparative Efficacy of Interferon-Free Antivirals for Treatment-Naïve Hepatitis C Genotype 1.
18:A576-A576.
2015
-
Use of Economic Evaluations of Health Technologies In Dutch Healthcare Decision-Making: Barriers And Facilitators.
18:A540-A540.
2015
-
Zrx Mcdm: A Fully Flexible Tool to Support The Local Adaptation of Multiple-Criteria Decision Criteria In Health Care.
18:A703-A703.
2015
-
An Assessment of the Association Between Rural Status and Health Service Resource Use Among Patients With Ankle Sprains in Ontario.
17:A388-A388.
2014
-
Comparative Efficacy and Safety of Empagliflozin with Other Anti-Diabetic Drugs for the Treatment of Patients with Type 2 Diabetes Mellitus Who are Failing Insulin.
17:A332-A333.
2014
-
Comparative Efficacy and Safety of Empagliflozin with Other Antidiabetic Drugs for the Third Line Treatment of Type 2 Diabetes Mellitus.
17:A333-A333.
2014
-
Comparative Efficacy and Safety of Empagliflozin with Other Oral Antidiabetic Drugs for the Second Line Treatment of Type 2 Diabetes Mellitus.
17:A333-A333.
2014
-
Economic Evaluation of Bevacizumab Versus Ranibizumab in Neovascular Age-Related Macular Degeneration in China.
17:A782-A782.
2014
-
Impact of Demographics on Health Preferences in China: An Exploratory Analysis of China EQ-5D-5L Valuation Study.
17:A753-A753.
2014
-
Incretin Therapy and Risk of Pancreatitis in Type 2 Diabetes Mellitus: Systematic Review of Randomized and Non-Randomized Studies.
17:A740-A741.
2014
-
The Costs of Diagnosis and Treatment of Ankle Sprains and Fractures, 1980-2013: A Systematic Review.
17:A377-A377.
2014
-
PSY40 Indirect Comparison Of The Efficacy Of Recombinant Factor Viii Fc Fusion Protein And Other Factor Viii Products For ProphylaxisModeling The Effect Of Compliance.
17:a230.
2014
-
PSY41 Indirect Comparison Of The Efficacy Of Recombinant Factor Ix Fc Fusion Protein And Other Factor Ix Products For Prophylaxis: Simulating The Effect Of Compliance On Real-World Effectiveness.
17:a230.
2014
-
Health Utility Scores in Alzheimer’s Disease: Differences Based on Calculation With American and Canadian Preference Weights.
17:77-83.
2014
-
Assessing the Value of Symptom Relief for Patients with Gastroesophageal Reflux Disease Treatment: Willingness to Pay Using a Discrete Choice Experiment.
16:588-598.
2013
-
Measuring the Quality of a Childhood Cancer Care Delivery System: Assessing Stakeholder Agreement.
16:639-646.
2013
-
Measuring the Quality of a Childhood Cancer Care Delivery System: Quality Indicator Development.
16:647-654.
2013
-
Health utilities index®: Extending the age range to pre-schoolers.
16:A35-A36.
2013
-
PRM174 Comparing EQ-5D valuation studies: A systematic review and methodological reporting checklist.
16:a44-a45.
2013
-
Core Domains for a Person-Focused Outcome Measurement System in Cancer (PROMS-Cancer Core) for Routine Care: A Scoping Review and Canadian Delphi Consensus.
16:76-87.
2013
-
Economic Appraisal of a Community-Wide Cardiovascular Health Awareness Program.
16:39-45.
2013
-
PDB14 Characteristics of the Aboriginal People with Diabetes in the South-Western of Ontario, Canada.
15:A495-A496.
2012
-
Cost-Effectiveness Analysis of Antiviral Treatments for HBeAg-Positive Chronic Hepatitis B in Canada.
15:894-906.
2012
-
PRM35 Empirical Examination of Starting Point Bias with the Bidding Game in a Willingness-to-Pay Analysis.
15:A165-A165.
2012
-
Guidelines for Health Technologies: Specific Guidance for Oncology Products in Canada.
15:580-585.
2012
-
An Exploratory Study of Response Shift in Health-Related Quality of Life and Utility Assessment Among Patients with Osteoarthritis Undergoing Total Knee Replacement Surgery in a Tertiary Hospital in Singapore.
15:S72-S78.
2012
-
Economic Evaluation of Reamed versus Unreamed Intramedullary Nailing in Patients with Closed and Open Tibial Fractures: Results from the Study to Prospectively Evaluate Reamed Intramedullary Nails in Patients with Tibial Fractures (SPRINT) (vol 14, pg 450, 2011).
14:963-963.
2011
-
The Use of a Decision Board to Elicit Brazilian Patients' and Physicians' Preferences for Treatment: The Case of Lupus Nephritis.
14:S141-S146.
2011
-
Economic Evaluation of Reamed versus Unreamed Intramedullary Nailing in Patients with Closed and Open Tibial Fractures: Results from the Study to Prospectively Evaluate Reamed Intramedullary Nails in Patients with Tibial Fractures (SPRINT).
14:450-457.
2011
-
Use of a Disease-Specific Instrument in Economic Evaluations: Mapping WOMAC onto the EQ-5D Utility Index (vol 13, pg 873, 2010).
14:620-620.
2011
-
Cost-Effectiveness of Transdermal Nitroglycerin Use for Preterm Labor.
14:240-246.
2011
-
Cost-Utility of Laparoscopic Nissen Fundoplication versus Proton Pump Inhibitors for Chronic and Controlled Gastroesophageal Reflux Disease: A 3-Year Prospective Randomized Controlled Trial and Economic Evaluation.
14:263-273.
2011
-
Is the Health Utilities Index 3 valid for patients with ankylosing spondylitis?.
14:160-165.
2011
-
Erratum.
13:1065-1065.
2010
-
Functional Impairment and Disability across Mood States in Bipolar Disorder.
13:984-988.
2010
-
Use of a Disease-Specific Instrument in Economic Evaluations: Mapping WOMAC onto the EQ-5D Utility Index.
13:873-878.
2010
-
Analysis of Health Utility Data When Some Subjects Attain the Upper Bound of 1: Are Tobit and CLAD Models Appropriate?.
13:487-494.
2010
-
Conditionally Funded Field Evaluations: PATHs Coverage with Evidence Development Program for Ontario.
13:S8-S11.
2010
-
Contemporary Challenges in Deriving Summary Estimates of Comparative Effectiveness Using Meta-Analysis.
13:S15-S17.
2010
-
Using the Incremental Net Benefit Framework for Quantitative Benefit–Risk Analysis in Regulatory Decision-Making—A Case Study of Alosetron in Irritable Bowel Syndrome.
13:411-417.
2010
-
PMS58 HEALTH STATUS, PHYSICIAN, DAY PROCEDURES AND HOPITALIZATION COSTS ASSOCIATED WITH RHEUMATOID-ARTHRITIS IN ONTARIO.
13:A133-A133.
2010
-
PMS60 UTILIZING HEALTH SURVEY AND ADMINISTRATIVE DATA TO ESTIMATE THE BURDEN OF OSTEO-ARTHRITIS IN ONTARIO.
13:A133-A134.
2010
-
Impact of the 1997 Canadian Guidelines on the Conduct of Canadian-Based Economic Evaluations in the Published Literature.
13:328-334.
2010
-
Effects of Mode and Order of Administration on Generic Health-Related Quality of Life Scores.
12:1035-1039.
2009
-
The Impact of Drug Vintage on Patient Survival: A Patient-Level Analysis Using Quebec's Provincial Health Plan Data.
12:847-856.
2009
-
Cost-Effectiveness of Drug-Eluting Stents in a US Medicare Setting: A Cost-Utility Analysis with 3-Year Clinical Follow-Up Data.
12:649-656.
2009
-
Validity of a Short Functioning Test (FAST) in Brazilian Outpatients with Bipolar Disorder.
12:624-627.
2009
-
A Cost-Effectiveness Model Comparing Endovascular Repair to Open Surgical Repair of Abdominal Aortic Aneurysms in Canada.
12:245-252.
2009
-
Comparing the Health Utilities Index Mark 3 (HUI3) with the Short Form-36 Preference-Based SF-6D in Chronic Kidney Disease.
12:340-345.
2009
-
QALYs: The Basics.
12:S5-S9.
2009
-
Assessing the Impact of Censoring of Costs and Effects on Health-Care Decision-Making: an Example Using the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study.
11:365-375.
2008
-
Time and Expected Value of Sample Information Wait for No Patient.
11:522-526.
2008
-
Validation of a Prediction Model to Estimate Health Utilities Index Mark 3 Utility Scores from WOMAC Index Scores in Patients with Osteoarthritis of the Hip.
11:470-477.
2008
-
A Study on Indirect and Intangible Costs for Patients with Knee Osteoarthritis in Singapore.
11:S84-S90.
2008
-
Applying the Expectancy-Value Model to Understand Health Values.
11:S61-S68.
2008
-
The Association of Body Mass Index with Health-Related Quality of Life: An Exploratory Study in a Multiethnic Asian Population.
11:S105-S114.
2008
-
Validity, Feasibility and Acceptability of Time Trade-Off and Standard Gamble Assessments in Health Valuation Studies: A Study in a Multiethnic Asian Population in Singapore.
11:S3-S10.
2008
-
Measuring Patient Preferences for Colorectal Cancer Screening Using a Choice-Format Survey.
10:415-430.
2007
-
Assessing Differences in Utility Scores: A Comparison of Four Widely Used Preference-Based Instruments.
10:256-265.
2007
-
PAR3 PRODUCTIVITY BENEFITS FROM CONTROLLED-RELEASE VS SHORT ACTING OPIOIDS FOR TREATMENT OF PERSISTENT MODERATE TO SEVERE OSTEOARTHRITIS (OA) PAIN OF THE HIP/KNEE.
8:A24-A25.
2005
-
MS3 ECONOMIC EVALUATION OF CONTROLLED-RELEASE OXYCODONE (OXYCONTIN®TABLETS) (CRO) VERSUS OXYCODONE/ACETAMINOPHEN (PERCOCET®) (OXY/APAP) FOR OSTEOARTHRITIS PAIN OF THE HIP OR KNEE.
8:241-241.
2005
-
PMDI9: COMMUNITY OR PATIENT PREFERENCES FOR COST-UTILITY ANALYSES: DOES IT MATTER?.
6:298-298.
2003
-
Oseltamivir for Treatment of Influenza in Healthy Adults: Pooled Trial Evidence and Cost-Effectiveness Model for Canada.
6:116-125.
2003
-
PWM5 PRELIMINARY VALIDATION OF A NEW DISEASE-SPECIFIC UTILITY MEASURE FOR ERECTILE DYSFUNCTION.
5:588-588.
2002
-
Cost-Effectiveness and Cost-Utility of Long-Term Management Strategies for Heartburn.
5:312-328.
2002
-
PHP50 HEALTH-RELATED QUALITY OF LIFE IN HEMOPHILIA AND VON WILLEBRAND's DISEASE: MEASUREMENT PROPERTIES OF THE HEALTH UTILITIES INDEX.
5:158-158.
2002
-
PMA3: DOES WHERE YOU LIVE AFFECT IF AND HOW YOU DISCOUNT FUTURE COSTS AND BENEFITS IN ECONOMIC EVALUATION? SHOULD IT?.
4:182.
2001
-
POD7: THE EF-VAS: A PREFERENCE-BASED SELFADMINISTRATION INSTRUMENT FOR ASSESSING THE IMPACT OF ERECTILE DYSFUNCTION (ED) AND ED TREATMENT.
4:468-469.
2001
-
PQP7: IS COMPLIANCE WITH DRUG TREATMENT CORRELATED WITH HEALTH RELATED QUALITY OF LIFE?.
4:179-179.
2001
-
A Multinational Pharmacoeconomic Evaluation of Acute Major Depressive Disorder (MDD): a Comparison of Cost-Effectiveness Between Venlafaxine, SSRIs and TCAs.
4:16-31.
2001
-
TPDM6: DETERMINING COST DRIVERS IN A COSTEFFECTIVENESS ANALYSIS OF THREE TREATMENTS FOR OVERACTIVE BLADDER.
2:152-152.
1999
-
WMM2: ECONOMIC EVALUATION OF PROSPECTIVE MULTINATIONAL CLINICAL TRIALS: A MODELING APPROACH.
2:229-229.
1999
-
PCV10: A HEALTH ECONOMIC EVALUATION OF HORMONE REPLACEMENT THERAPY IN BELGIUM.
2:27-27.
1999
-
MGA5 Health Utilities Index: Further Evidence of Responsiveness.
1:41-41.
1998
-
MGA6 Survey Strategies in the Revision of the Guidelines for Economic Evaluation: Canada.
1:41-42.
1998
-
UT2 Practical Applications of the Health Utilities Index.
1:93-93.
1998
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)